The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea

Biomarkers. 2012 Sep;17(6):490-7. doi: 10.3109/1354750X.2012.687014. Epub 2012 May 23.

Abstract

Serum mid-regional pro-atrial natriuretic peptide (MR-proANP) and pro-adrenomedullin (MR-proADM) are novel biomarkers for acute heart failure (AHF). Like other AFH biomarkers, the performance of these tests are affected by the presence of clinical variables such as renal failure and obesity. In a substudy of the Biomarkers from Acute Heart Failure Study, we show that diabetes did not influence the performance of these markers with regards to AHF diagnosis or 90-day all cause death. However, in patients without AHF, increased MR-proADM alone was associated with the presence of diabetes.

MeSH terms

  • Acute Disease
  • Adrenomedullin / blood*
  • Adult
  • Aged
  • Aged, 80 and over
  • Atrial Natriuretic Factor / blood*
  • Biomarkers / blood
  • Clinical Trials as Topic
  • Diabetes Mellitus / blood*
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / mortality
  • Dyspnea / blood
  • Dyspnea / diagnosis*
  • Dyspnea / mortality
  • Female
  • Heart Failure / blood
  • Heart Failure / diagnosis*
  • Heart Failure / mortality
  • Humans
  • Kaplan-Meier Estimate
  • Linear Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Peptide Fragments / blood*
  • Prognosis
  • Protein Precursors / blood*
  • ROC Curve

Substances

  • Biomarkers
  • Peptide Fragments
  • Protein Precursors
  • mid-regional pro-adrenomedullin, human
  • midregional pro-atrial natriuretic peptide, human
  • Adrenomedullin
  • Atrial Natriuretic Factor